Beneficial Ownership Report · SCHEDULE 13G/A
Beta Bionics, Inc.
BBNXNASDAQEQUITYCurrent
Beneficial Ownership Report
Structured filing — SCHEDULE 13G/A
primary_doc.xml
Amendment · This filing reports the amendment as submitted.
Subject company
- Company
- Beta Bionics, Inc.
- Company CIK
- 0001674632
- Street
- 11 HUGHES
- City
- IRVINE
- State / country code
- CA
- Postal code
- 92618
Statement details
- Amendment number
- 1
- Security class
- Common Stock, par value $0.0001 per share
- Event date
- 09/30/2026
- Rule designation
- Rule 13d-1(c)
Reporting person 1
- Name
- Point72 Asset Management, L.P.
- Citizenship / organization
- DE
- Reporting person type
- PN
- Group designation
- b
- Aggregate amount owned
- 967,144.00
- Percent of class
- 1.8
- Sole voting power
- 0.00
- Shared voting power
- 967,144.00
- Sole dispositive power
- 0.00
- Shared dispositive power
- 967,144.00
- Aggregate excludes certain shares
- N
Reporting person 2
- Name
- Point72 Capital Advisors, Inc.
- Citizenship / organization
- DE
- Reporting person type
- CO
- Group designation
- b
- Aggregate amount owned
- 967,144.00
- Percent of class
- 1.8
- Sole voting power
- 0.00
- Shared voting power
- 967,144.00
- Sole dispositive power
- 0.00
- Shared dispositive power
- 967,144.00
- Aggregate excludes certain shares
- N
Reporting person 3
- Name
- Steven A. Cohen
- Citizenship / organization
- X1
- Reporting person type
- IN
- Group designation
- b
- Aggregate amount owned
- 967,144.00
- Percent of class
- 1.8
- Sole voting power
- 0.00
- Shared voting power
- 967,144.00
- Sole dispositive power
- 0.00
- Shared dispositive power
- 967,144.00
- Aggregate excludes certain shares
- N
Item 1
Issuer
Beta Bionics, Inc.
Principal executive office address
11 Hughes, Irvine, California 92618
Item 2
Citizenship
Point72 Asset Management is a Delaware limited partnership. Point72 Capital Advisors Inc. is a Delaware corporation. Mr. Cohen is a United States citizen.
Filing person
This statement is filed by: (i) Point72 Asset Management, L.P. ("Point72 Asset Management") with respect to the shares of common stock, par value $0.0001 per share ("Shares"), of Beta Bionics, Inc. (the "Issuer") held by an investment fund it manages; (ii) Point72 Capital Advisors, Inc. ("Point72 Capital Advisors Inc.") with respect to Shares held by an investment fund managed by Point72 Asset Management; and (iii) Steven A. Cohen ("Mr. Cohen") with respect to Shares beneficially owned by Point72 Asset Management and Point72 Capital Advisors Inc. Each of Cubist Systematic Strategies, LLC and Point72 Europe (London) LLP are relying advisers on the Form ADV of Point72 Asset Management and each acts as a sub-advisor with respect to a portion of the Shares reported herein.
Principal business or residence address
The address of the principal business office of Point72 Asset Management, Point72 Capital Advisors Inc., and Mr. Cohen is 72 Cummings Point Road, Stamford, CT 06902.
Item 3
Not applicable indication
Y
Item 4
Percent of class
1.8%
Amount beneficially owned
The information required by Item 4(a) is set forth in Row 9 of the cover page for each of the Reporting Persons and is incorporated herein by reference. Such information is as of the close of business on September 30, 2026. Point72 Asset Management, Point72 Capital Advisors Inc., and Mr. Cohen own directly no Shares. Pursuant to an investment management agreement, Point72 Asset Management maintains investment and voting power with respect to the securities held by an investment fund it manages. Point72 Capital Advisors Inc. is the general partner of Point72 Asset Management. Mr. Cohen controls each of Point72 Asset Management and Point72 Capital Advisors Inc. The filing of this statement should not be construed as an admission that any of the foregoing persons or any Reporting Person is, for the purposes of Section 13 of the Securities Exchange Act of 1934, the beneficial owner of the Shares reported herein. The percentage set forth in this Schedule 13G is calculated based upon an aggregate of 53,946,211 Shares outstanding, which is the sum of: (i) 44,989,688 Shares outstanding as of July 27, 2026, as reported in the Issuer's Quarterly Report on Form 10-Q for the quarterly period ended June 30, 2026, filed with the Securities and Exchange Commission (the "SEC") on July 29, 2026; (ii) 7,652,175 Shares issued in the offering described in the Issuer's Prospectus filed pursuant to Rule 424(b)(5) with the SEC on September 17, 2026; and (iii) 1,304,348 Shares issued pursuant to the full exercise of the underwriters' option to purchase additional Shares, as disclosed in the press release issued by the Issuer on September 17, 2026.
Sole voting power
The information required by Item 4(c)(i) is set forth in Row 5 of the cover page for each of the Reporting Persons and is incorporated herein by reference. Such information is as of the close of business on September 30, 2026.
Shared voting power
The information required by Item 4(c)(ii) is set forth in Row 6 of the cover page for each of the Reporting Persons and is incorporated herein by reference. Such information is as of the close of business on September 30, 2026.
Sole dispositive power
The information required by Item 4(c)(iii) is set forth in Row 7 of the cover page for each of the Reporting Persons and is incorporated herein by reference. Such information is as of the close of business on September 30, 2026.
Shared dispositive power
The information required by Item 4(c)(iv) is set forth in Row 8 of the cover page for each of the Reporting Persons and is incorporated herein by reference. Such information is as of the close of business on September 30, 2026.
Item 5
Not applicable indication
N
Ownership of 5% or less
Y
Item 6
Not applicable indication
N
Ownership on behalf of another person
See Item 2(a).
Item 7
Not applicable indication
Y
Item 8
Not applicable indication
Y
Item 9
Not applicable indication
Y
Item 10
Not applicable indication
N
Certifications
By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11.
Signature 1
- Reporting person
- Point72 Asset Management, L.P.
- Signed
- /s/ Jason M. Colombo
- Title
- Jason M. Colombo, Authorized Person
- Date
- 11/16/2026
Signature 2
- Reporting person
- Point72 Capital Advisors, Inc.
- Signed
- /s/ Jason M. Colombo
- Title
- Jason M. Colombo, Authorized Person
- Date
- 11/16/2026
Signature 3
- Reporting person
- Steven A. Cohen
- Signed
- /s/ Jason M. Colombo
- Title
- Jason M. Colombo, Authorized Person
- Date
- 11/16/2026
Company context
We are a commercial-stage medical device company engaged in the design, development and commercialization of innovative solutions to improve the health and quality of life of insulin-requiring people with diabetes (PWD) by utilizing advanced adaptive closed-loop algorithms to simplify and improve the treatment of their disease. Diabetes is a serious, chronic and often lifelong condition with no known cure that is characterized by extended periods of elevated levels of glucose in the bloodstream, or hyperglycemia, resulting from the body’s inability to either produce or effectively utilize the hormone insulin. To treat their diabetes, PWD must undergo a rigorous regimen of daily insulin substitution, as elevated levels of glucose in the blood over time can lead to serious and often life-threatening cardiovascular, metabolic and nervous system complications. Despite decades of innovation that have advanced the quality of care available, a significant unmet need remains as the vast majority of PWD still cannot manage their diabetes effectively. Our product, the iLet Bionic Pancreas (iLet), is the first insulin delivery device cleared by the U.S. Food and Drug Administration (FDA) to utilize adaptive closed-loop algorithms to autonomously determine every insulin dose without requiring a user to count carbohydrate intake. We believe this marks a significant advancement over other insulin delivery technologies by offering a differentiated combination of improved glycemic control an